Skip to main content

Table 1 Antimicrobial activity of omadacycline against Gram-positive cocci organisms

From: Antimicrobial activity of omadacycline in vitro against bacteria isolated from 2014 to 2017 in China, a multi-center study

Organism/organism group (number of isolates)

Number (cumulative %) of isolates at MIC (mg/L) of:

MIC50

MIC90

%S

%R

<0.03

0.03

0.06

0.12

0.25

0.5

1

2

Staphylococcus aureus(197)

0 (0.0)

1 (0.5)

43 (22.3)

118 (82.2)

27 (95.9)

5 (98.5)

2 (99.5)

1 (100.0)

0.12

0.25

98.5a

0.5

  Methicillin-susceptible (100)

0 (0.0)

1 (1.0)

27 (28.0)

69 (97.0)

2 (99.0)

1 (100.0)

  

0.12

0.12

100.0

0.0

  Methicillin-resistant (97)

  

16 (16.5)

49 (67.0)

25 (92.8)

4 (96.9)

2 (99.0)

1 (100.0)

0.12

0.25

96.9

1.0

  Tetracycline-resistant (116)

0 (0.0)

1 (0.9)

19 (17.2)

67 (75.0)

21 (93.1)

5 (97.4)

2 (99.1)

1 (100.0)

0.12

0.25

97.4

0.9

  Tigecycline-non-susceptible (1)

  

0 (0.0)

1 (100.0)

      

100.0

0.0

Enterococcus spp. (25)

0 (0.0)

13 (52.0)

7 (80.0)

5 (100.0)

    

0.03

0.12

  

  Enterococcus faecalis (9)

0 (0.0)

2 (22.2)

4 (66.7)

9 (100.0)

    

0.06

 

100.0

0.0

  Enterococcus faecium (16)

0 (0.0)

11 (68.8)

3 (87.5)

2 (100.0)

    

0.03

0.12

  

Streptococcus pneumoniae (59)

6 (10.2)

21 (45.8)

27 (91.5)

3 (96.6)

2 (100.0)

   

0.06

0.06

96.6

0.0

  Penicillin-susceptible (25)

3 (12.0)

8 (44.0)

11 (88.0)

1 (92.0)

2 (100.0)

   

0.06

0.12

92.0

0.0

  Penicillin-intermediate (15)

1 (6.7)

6 (46.7)

7 (93.3)

1 (100.0)

    

0.06

0.06

100.0

0.0

  Penicillin-resistant (19)

2 (10.5)

7 (47.3)

9 (94.7)

1 (100.0)

    

0.06

0.06

100.0

0.0

  Tetracycline-resistant (53)

4 (7.5)

18 (41.5)

26 (90.6)

3 (96.2)

2 (100.0)

   

0.06

0.06

96.2

0.0

  Tigecycline-non-susceptible (3)

0 (0.0)

1 (33.3)

0 (33.3)

0 (33.3)

2 (100.0)

   

0.25

 

33.3

0.0

Viridans group streptococci (25)

14 (56)

8 (88.0)

1 (92.0)

1 (96.0)

1 (100.0)

   

0.015

0.06

  

  Streptococcus anginosus group (21)

11 (52.4

7 (85.7)

1 (90.5)

1 (95.2)

1 (100.0)

   

0.015

0.06

95.2

0.0

  Tetracycline-resistant (14)

5 (35.7)

7 (85.7)

1 (92.9)

1 (100.0)

    

0.03

0.06

100.0

0.0

  Tigecycline-non-susceptible (1)

   

0 (0.0)

1 (100.0)

     

0.0

0.0

β-haemolytic streptococci (27)

1 (3.7)

11 (44.4)

6 (66.7)

8 (96.3)

1 (100.0)

   

0.06

0.12

  

  Tetracycline-resistant (20)

1 (5.0)

4 (25.0)

6 (55.0)

8 (95.0)

1 (100.0)

   

0.06

0.12

  

  Streptococcus pyogenes (8)

1 (12.5)

7 (100.0)

      

0.03

 

100.0

0.0

  1. a Applying FDA identified breakpoints for ABSSSIs